AGM CHAIR'S ADDRESS & MANAGING DIRECTOR PRESENTATION

Perth, Australia; 19 November 2026 - Argenica Therapeutics Limited (ASX: AGN) ("Argenica" or the "Company"), is pleased to provide below copies of the Chair's Address and Managing Director Presentation given at its Annual General Meeting held at 2.00PM (WST) on 19 November 2026.

Chair's Address – Jeannie Joughin

The Agenda today will comprise the Chair's Address, followed by the formal business and voting on the Resolutions as set out in the Notice of Meeting. I will then hand over to our MD and CEO, Liz Dallimore who will make a presentation and be happy to address questions. We would also welcome you to stay after the meeting.

A copy of the Presentation will be made available on the ASX. I also note an ASX announcement on FDA feedback has just been released. Liz will address this announcement in her presentation.

2026 was a pivotal year for the Company with the readout from its Phase 2 clinical trial of lead drug candidate ARG-007 (now named xaranetide) in acute ischaemic stroke patients.

The primary objective of the trial was to test the safety of xaranetide in AIS patients presenting to emergency departments and undergoing endovascular thrombectomy, which was successfully met. Demonstrating the safety in this patient population represents a significant milestone in neurology drug development.

The Phase 2 trial also explored the drug's effect on a number of predefined efficacy measures and identified more severe stroke patients showing a treatment benefit with xaranetide.

In a post-hoc analysis correcting for baseline stroke severity, statistically significant improvements in FDA validated functional outcomes were also observed in patients with larger infarct cores. These patients typically have the worst outcomes post stroke, making them the group with the most to gain from an effective neuroprotective treatment.

On the strength of the trial safety and functional efficacy data, Argenica is finalising the design of a targeted late-stage AIS trial in consultation with its global stroke Clinical Advisory Committee and potential pharmaceutical partners.

Globally, stroke is one of the leading causes of mortality and disability and there are substantial economic costs for poststroke care. However, despite considerable and ongoing research, there are currently no universally marketed treatments capable of protecting the brain from the damage following stroke. The search for effective neuroprotective agents that can be easily administered remains urgent, and Argenica is driving xaranetide to address this critical unmet clinical need, and to realise the large commercial opportunity in offering an effective treatment.

During the year xaranetide has also demonstrated significant neuroprotection in a number of preclinical traumatic brain injury & concussion studies. Argenica now has a growing body of evidence across mild, moderate and severe TBI injury models and is considering next steps to advance xaranetide's development in this indication.

We appreciate the ongoing support of all our shareholders, the dedication of our employees, research and clinical collaborators, and look forward to continuing our progress in the coming year.

This announcement has been approved for release by the Board of the Company.

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica Therapeutics Limited (ASX: AGN) is a clinical-stage biotechnology company developing innovative neuroprotective therapeutics to improve outcomes for patients following stroke and other acute neurological injuries. The Company's lead drug candidate, xaranetide, is designed to protect vulnerable brain tissue by reducing cell death and limiting secondary damage after an ischaemic event. With a strong scientific foundation and a clear clinical development pathway, Argenica is focused on advancing novel treatments that have the potential to significantly improve patient recovery and transform the standard of care in acute neurology.